Holen Sie sich die Stockscreener-App
2.44
0.00%
0.00
Handel nachbörslich:
2.48
0.04
+1.64%
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
Does Cardiff Oncology Inc. qualify in momentum factor screeningMarket Risk Report & Long-Term Growth Stock Strategies - Newser
Forecasting Cardiff Oncology Inc. price range with options data2025 Technical Patterns & AI Driven Price Predictions - Newser
Published on: 2025-08-15 06:29:30 - newsyoung.net
How Cardiff Oncology Inc. stock performs during market volatilityTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
New Product Launches: Will They Boost Cardiff Oncology Inc. Stock in 2025Long-Term Safety Investment Analysis Report - Newser
Clinical trial by SD company proves promising for drug that targets colorectal cancer - NewsBreak: Local News & Alerts
Q3 EPS Forecast for Cardiff Oncology Decreased by Analyst - Defense World
Analyzing drawdowns of Cardiff Oncology Inc. with statistical toolsDaily Technical Forecast for Quick Gains - Newser
Has Cardiff Oncology Inc. found a price floorReliable Setup Screener with Low Risk - Newser
What earnings revisions data tells us about Cardiff Oncology Inc.Minimal Risk Growth Investment Opportunity Analysis - Newser
Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday - Defense World
Cardiff Oncology Price Target Cut to $10 by H.C. Wainwright. - AInvest
H.C. Wainwright lowers Cardiff Oncology stock price target on trial data - Investing.com Nigeria
Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom - insights.citeline.com
How does Cardiff Oncology Inc. generate profit in a changing economyAchieve breakthrough gains with smart trades - Jammu Links News
What is the dividend policy of Cardiff Oncology Inc. stockGet real-time alerts on top stocks - Jammu Links News
Why is Cardiff Oncology Inc. stock attracting strong analyst attentionFree Popular Stock Recommendations - Jammu Links News
Should I hold or sell Cardiff Oncology Inc. stock in 2025Maximize returns with disciplined investment techniques - Jammu Links News
What institutional investors are buying Cardiff Oncology Inc. stockUnstoppable profit momentum - Jammu Links News
Is Cardiff Oncology Inc. stock overvalued or undervaluedMarket-crushing stock picks - Jammu Links News
How strong is Cardiff Oncology Inc. company’s balance sheetFree Risk Assessment Services - Jammu Links News
What analysts say about Cardiff Oncology Inc. stockGrow your wealth with proven stock picks - Jammu Links News
What drives Cardiff Oncology Inc. stock priceUnrivaled growth potential - Jammu Links News
What is the risk reward ratio of investing in Cardiff Oncology Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What catalysts could drive Cardiff Oncology Inc. stock higher in 2025Free Investment Risk Control - Jammu Links News
Is Cardiff Oncology Inc. a good long term investmentHigh-return market picks - Jammu Links News
When is Cardiff Oncology Inc. stock expected to show significant growthSuperior returns - Jammu Links News
Is Cardiff Oncology Inc. a growth stock or a value stockNavigate the market with precision tools - Jammu Links News
William Blair Raises Earnings Estimates for Cardiff Oncology - Defense World
Investors Purchase Large Volume of Cardiff Oncology Put Options (NASDAQ:CRDF) - Defense World
Both Individual Investors Who Control a Good Portion of Cardiff Oncology, Inc. (NASDAQ:CRDF) Along With Institutions Must Be Dismayed After Last Week's 42% Decrease - 富途牛牛
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - inkl
Cardiff Oncology Insiders Land Bargain With Gains Of US$244k - Yahoo Finance
Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
Cardiff Oncology (CRDF.O) Plummets 27%: What's Behind the Sharp Intraday Move? - AInvest
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2 - Benzinga
Cardiff Oncology Plunges 26.59% on Earnings Miss - AInvest
Cardiff Oncology 2025 Q2 Earnings Financial Struggles as Net Income Declines 18.4% - AInvest
Cardiff Oncology Reports Q2 2025 Financial Results - TipRanks
Cardiff Oncology shares fall 26.89% after-hours after reporting a wider Q2 net loss. - AInvest
Cardiff Oncology shares plunge after Q2 earnings miss By Investing.com - Investing.com South Africa
Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004) - TradingView
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cardiff Oncology: Q2 Earnings Snapshot - San Francisco Chronicle
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com
Cardiff Oncology reports results from colorectal cancer trial - Seeking Alpha
Cardiff Oncology reports positive data from colorectal cancer trial By Investing.com - Investing.com Nigeria
Cardiff Oncology reports positive data from colorectal cancer trial - Investing.com Australia
Cardiff Oncology Announces Positive Data from Ongoing Randomized - GuruFocus
Cardiff Oncology Announces Positive Data from Ongoing - GlobeNewswire
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):